VICKI FITZGERALD: Open Payments
NPI 1154563005 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,013 in 106 payments from 19 companies in 2025. Trend: 2023 $1,588 · 2024 $1,520 · 2025 $2,013
Food & beverage: $2,013
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $291 |
| GENZYME CORPORATION | 11 | $230 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $212 |
| ABBVIE INC. | 20 | $200 |
| Aimmune Therapeutics, Inc. | 10 | $200 |
| Ardelyx, Inc. | 9 | $166 |
| Phathom Pharmaceuticals, Inc. | 3 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $96 |
| QOL Medical, LLC | 4 | $94 |
| Ipsen Biopharmaceuticals, Inc | 4 | $79 |
Products named: DUPIXENT, REZDIFFRA, XIFAXAN, ZENPEP, IBSRELA, VOQUEZNA, ENTYVIO, Sucraid.
Industry payments across MS — which companies pay providers there.
